Yumanity Therapeutics, Inc. (YMTX) is a late-stage biotherapeutics business developing therapeutics for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Parkinson’s disease, and Alzheimer’s disease. Its drug discovery portfolio allows the rapid screening for possible disease-modifying therapeutics by overpowering the protein’s toxicity linked to neurogenerative diseases.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
YMTX stock price during the regular trading of March 17, 2022, was down by 5.66% to be $1.00. Its price rocketed as of this writing in the premarket session of March 18, 2022, by 12.0%.
YMTX: Events and Happenings
On February 17, 2022, YMTX reported the exploration of strategic substitutes intending to improve stockholder value. On February 04, 2022, YMTX announced that it granted non-statutory stock options as an inducement material to its two employees for the acquisition of a cumulative 6,000 shares of the company’s common stock. The options had a per-share exercise price of $2.19.
On January 19, 2022, YMTX updated on the receipt of notification of clinical hold placement by FDA on its IND application for YTX-7739. The FDA permitted its already prearranged single-dose clinical study to proceed. On January 11, 2022, YMTX informed the press regarding the company’s corporate developments including the research milestone achieved for its ALS and FTLD platform.
YMTX: Key Financials
On November 15, 2021, YMTX released the third quarter 2021 unaudited financial statement for the quarter ended September 30, 2021. Some important aspects are highlighted below.
Collaboration revenue in Q3 2021 was $1.63 million in comparison to $3.3 million during the same quarter of 2020. The company missed the estimation of revenue by $298 thousand and collaboration revenues declined by $1.6 million approximately YoY.
Net losses per share basic and diluted in Q3 2021 were $10.0 million or $0.97 versus $6.4 million or $2.96 in the corresponding 2020 quarter. The company’s EPS inclined YoY and it surpassed the EPS estimations by $0.25.
The stock price of YMTX dropped by more than 90% in the last year as the outcome of the constraints imposed due to the pandemic. The company’s stock recently fell in the premarket session despite any clear reason as there is no official announcement or event update from it. The company is also gearing for the earnings release as the revenue outlook is $1.8 million and EPS is -$1.05.